Gathering the record
Relay is organizing the evidence and source boundaries.
Experimental ERR agonist small molecule
SLU-PP-332 is a laboratory small molecule that activates estrogen-related receptors and has been described as an exercise-mimetic research tool in mice.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
SLU-PP-332 is an experimental small molecule, not a peptide. It activates estrogen-related receptors, proteins that help regulate energy use and oxidative metabolism.
Mouse studies use it as an exercise-mimetic research tool to ask whether activating these pathways changes endurance, muscle fibers, energy expenditure, or metabolic measures without exercise.
In sedentary mice, SLU-PP-332 increased oxidative muscle fibers and endurance. Obesity-model studies reported energy and metabolic signals. Later chemistry work developed different analogs partly because the parent compound has oral-exposure limitations. No administered-human outcome study was located.
Human pharmacokinetics, receptor selectivity, target engagement, clinical effectiveness, organ toxicity, reproductive effects, interactions, and long-term safety remain unknown. Mouse endurance is not evidence of human exercise replacement or performance benefit.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
Published research investigated SLU-PP-332 in sedentary mice and measured endurance alongside oxidative muscle-fiber and metabolic changes.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Animal and mechanistic evidence only; parent compound has oral-bioavailability limitations.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Human pharmacokinetics, selectivity, target engagement, efficacy, organ toxicity, reproductive effects, and long-term safety.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: No verified study administered SLU-PP-332 to human participants. Mouse endurance and metabolism outcomes cannot establish human performance, exercise replacement, clinical benefit, pharmacokinetics, or safety. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
No administered-human study was located.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Human pharmacokinetics, selectivity, target engagement, efficacy, organ toxicity, reproductive effects, and long-term safety.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Mechanisms
Mouse studies report oxidative-muscle, endurance, and metabolic changes. Later analog work specifically sought better oral exposure, underscoring that the parent compound is not a clinically validated oral therapy.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Controlled animal study
Mice
SLU-PP-332 increased oxidative muscle fibers and endurance in sedentary mice.
Study administration: SLU-PP-332 versus vehicle
Limitations: Mouse study using experimental exposure; no human outcomes.
Controlled animal metabolic study
Mouse obesity models
Endpoints were not fully described in the current record.
Mouse experiments reported increased energy expenditure and improved selected metabolic measures.
Study administration: Not stated in the current record.
Limitations: Animal-model and exposure differences limit translation.
Medicinal chemistry and preclinical pharmacology study
Population not stated.
Endpoints were not fully described in the current record.
New analogs were developed to address limitations including oral exposure of the parent research tool.
Study administration: Not stated in the current record.
Limitations: Analog findings do not validate SLU-PP-332 or establish human use.
Safety snapshot
Current evidence cannot yet resolve: Human pharmacokinetics, selectivity, target engagement, efficacy, organ toxicity, reproductive effects, and long-term safety.
No direct evidenceAn absence of adequate evidence is not evidence of benefit, harm, or equivalence.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryPreclinical; no FDA-approved product and no administered-human outcome study located. Human pharmacokinetics, selectivity, target engagement, efficacy, organ toxicity, reproductive effects, and long-term safety.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 36988910
PMID 37739806
PMID 41421047